Turning Over a New Leaf-Pharmacologic Therapy in Obstructive Sleep Apnea.

Despite extensive research, there is currently no approved drug for obstructive sleep apnea (OSA) treatment. OSA is a heterogeneous condition that involves multiple dominating pathophysiological traits. Drug development in this field needs to address both pathophysiological mechanisms and associated comorbid conditions in order to meet requirements for long-term therapy in OSA. Several drug candidates have been proposed and ongoing phase II trials that target various forms of sleep-disordered breathing have been initiated. The field is moving toward tailored therapeutic approaches in patients with OSA.

• Publication year

  2022

• Venue

  Sleep Medicine Clinics

• Publication date

  2022-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jsmc.2022.06.010PMID 36150807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Randomized Controlled Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea.

  2022cited by this paper
• BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

  2021cited by this paper
• Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea

  2021cited by this paper
• Impact of cold and flu medication on obstructive sleep apnoea and its underlying traits: A pilot randomized controlled trial

  2021cited by this paper
• Polymorphism of the Serotonin Transporter Gene and the Peripheral 5-Hydroxytryptamine in Obstructive Sleep Apnea: What Do We Know and What are We Looking for? A Systematic Review of the Literature

  2021cited by this paper
• Associations Between Sleep Position and Nocturnal Gastroesophageal Reflux: A Study Using Concurrent Monitoring of Sleep Position and Esophageal pH and Impedance

  2021cited by this paper
• Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in Obstructive Sleep Apnea: An Analysis of Subgroups Adherent or Nonadherent to Obstructive Sleep Apnea Treatment.

  2021cited by this paper
• Metrics of Sleep Apnea Severity: Beyond the AHI.

  2021cited by this paper
• Addition of zolpidem to combination therapy with atomoxetine‐oxybutynin increases sleep efficiency and the respiratory arousal threshold in obstructive sleep apnoea: A randomized trial

  2021cited by this paper
• The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double‐blind, placebo‐controlled, randomised crossover trial

  2021cited by this paper
• Improving outcomes of hypoglossal nerve stimulation therapy: current practice, future directions, and research gaps. Proceedings of the 2019 International Sleep Surgery Society Research Forum

  2021cited by this paper
• Non-continuous positive airway pressure treatment options in obstructive sleep apnoea: A pathophysiological perspective.

  2021cited by this paper
• Gender Differences in the Context of Obstructive Sleep Apnea and Metabolic Diseases

  2021cited by this paper
• European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea

  2021cited by this paper
• Reboxetine Plus Oxybutynin for OSA Treatment

  2021cited by this paper
• Defining and Measuring Compliance With Oral Appliance Therapy

  2021cited by this paper
• Randomized trial on the effects of high-dose zopiclone on OSA severity, upper airway physiology and alertness.

  2020cited by this paper
• Update on Persistent Excessive Daytime Sleepiness in Obstructive Sleep Apnea.

  2020cited by this paper
• Effects of the Combination of Atomoxetine and Oxybutynin on Obstructive Sleep Apnea Endotypic Traits.

  2020cited by this paper
• What is a Clinically Meaningful Target for Positive Airway Pressure Adherence?

  2020cited by this paper
• Obstructive Sleep Apnea patients adhering to Continuous positive Airway Pressure: A randomized trial.

  2020cited by this paper
• Zolpidem increases sleep efficiency and the respiratory arousal threshold without changing sleep apnoea severity and pharyngeal muscle activity

  2020cited by this paper
• Weight Gain Induced by Continuous Positive Airway Pressure in Patients with Obstructive Sleep Apnea is Mediated by Fluid Accumulation: A Randomized Cross-Over Controlled Trial.

  2020cited by this paper
• Acetazolamide for Obstructive and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis.

  2020cited by this paper
• On the rise and fall of the apnea−hypopnea index: A historical review and critical appraisal

  2020cited by this paper
• Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial

  2020cited by this paper
• Influence of methazolamide on the human control of breathing: A comparison to acetazolamide

  2020cited by this paper
• Targeting Endotypic Traits with Medications for the Pharmacological Treatment of Obstructive Sleep Apnea. A Review of the Current Literature

  2019cited by this paper
• Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea

  2019cited by this paper
• Efficacy of pharmacotherapy for OSA in adults: A systematic review and network meta-analysis.

  2019cited by this paper
• Symptom Subtypes of Obstructive Sleep Apnea Predict Incidence of Cardiovascular Outcomes.

  2019cited by this paper
• [2018 ESC/ESH Guidelines for the management of arterial hypertension].

  2019cited by this paper
• The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.

  2019cited by this paper
• A randomized study of solriamfetol for excessive sleepiness in narcolepsy

  2019cited by this paper
• Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.

  2019cited by this paper
• Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.

  2019cited by this paper
• Carbonic anhydrase, obstructive sleep apnea and hypertension: Effects of intervention

  2019cited by this paper
• The relationship between obstructive sleep apnea hypopnea syndrome and gastroesophageal reflux disease: a meta-analysis

  2018cited by this paper
• 2018 ESC/ESH Guidelines for the management of arterial hypertension.

  2018cited by this paper
• Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial

  2018cited by this paper
• Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea

  2018cited by this paper
• Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement

  2018cited by this paper
• The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study

  2018cited by this paper
• Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial

  2018cited by this paper
• Phenotypic approaches to obstructive sleep apnoea - New pathways for targeted therapy.

  2018cited by this paper
• Challenges and perspectives in obstructive sleep apnoea

  2018cited by this paper
• Drug Therapy in Obstructive Sleep Apnea.

  2018cited by this paper
• Challenges in obstructive sleep apnoea.

  2018cited by this paper
• Effect of 4‐Aminopyridine on Genioglossus Muscle Activity during Sleep in Healthy Adults

  2017cited by this paper
• Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: paradoxical effects of zolpidem

  2017cited by this paper
• Sleep Apnea

  2017cited by this paper
• Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences.

  2017cited by this paper
• Effect of Antihypertensive Medications on the Severity of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis

  2016cited by this paper
• The Effect of Donepezil on Arousal Threshold and Apnea-Hypopnea Index. A Randomized, Double-Blind, Cross-Over Study.

  2016cited by this paper
• Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

  2016cited by this paper
• Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis

  2016cited by this paper
• The Combination of Supplemental Oxygen and a Hypnotic Markedly Improves Obstructive Sleep Apnea in Patients with a Mild to Moderate Upper Airway Collapsibility.

  2016cited by this paper
• Serotnin as a possible biomarker in obstructive sleep apnea.

  2016cited by this paper
• Zopiclone Increases the Arousal Threshold without Impairing Genioglossus Activity in Obstructive Sleep Apnea.

  2016cited by this paper
• CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea.

  2016cited by this paper
• Increased Carbonic Anhydrase Activity is Associated with Sleep Apnea Severity and Related Hypoxemia.

  2015cited by this paper
• Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension

  2014cited by this paper
• Identification of a pharmacological target for genioglossus reactivation throughout sleep.

  2014cited by this paper
• Arousal from sleep: implications for obstructive sleep apnea pathogenesis and treatment.

  2014cited by this paper
• Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study

  2014cited by this paper
• Trazodone increases the respiratory arousal threshold in patients with obstructive sleep apnea and a low arousal threshold.

  2014cited by this paper
• Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials

  2014cited by this paper
• Proof of Concept Trial of Dronabinol in Obstructive Sleep Apnea

  2013cited by this paper
• Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets.

  2013cited by this paper
• Acetazolamide attenuates the ventilatory response to arousal in patients with obstructive sleep apnea.

  2013cited by this paper
• Novel parameters for evaluating severity of sleep disordered breathing and for supporting diagnosis of sleep apnea-hypopnea syndrome

  2013cited by this paper
• Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs.

  2013cited by this paper
• Drug therapy for obstructive sleep apnoea in adults.

  2013cited by this paper
• Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure.

  2013cited by this paper
• Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure

  2013cited by this paper
• Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.

  2013cited by this paper
• Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial.

  2012cited by this paper
• Beneficial effect of donepezil on obstructive sleep apnea: a double-blind, placebo-controlled clinical trial.

  2012cited by this paper
• A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.

  2012cited by this paper
• Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea

  2012cited by this paper
• The European Sleep Apnoea Database (ESADA): report from 22 European sleep laboratories

  2011cited by this paper
• Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold.

  2011cited by this paper
• Pharmacological treatment of obstructive sleep apnea with a combination of pseudoephedrine and domperidone.

  2010cited by this paper
• Pathophysiology of sleep apnea.

  2010cited by this paper
• Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea.

  2010cited by this paper
• Modafinil effects during acute continuous positive airway pressure withdrawal: a randomized crossover double-blind placebo-controlled trial.

  2010cited by this paper
• Pharmacological approaches to the treatment of obstructive sleep apnoea

  2009cited by this paper
• Spironolactone Reduces Severity of Obstructive Sleep Apnea in Patients with Resistant Hypertension: a Preliminary Report

  2009cited by this paper
• Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.

  2009cited by this paper
• The effect of acid suppression on upper airway anatomy and obstruction in patients with sleep apnea and gastroesophageal reflux disease.

  2009cited by this paper
• Application of histamine or serotonin to the hypoglossal nucleus increases genioglossus muscle activity across the wake–sleep cycle

  2009cited by this paper
• Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea.

  2008cited by this paper
• Pharmacological treatment of sleep apnea: current situation and future strategies.

  2008cited by this paper
• Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness.

  2008cited by this paper
• Adherence to continuous positive airway pressure therapy: the challenge to effective treatment.

  2008cited by this paper
• Efficacy of mirtazapine in obstructive sleep apnea syndrome.

  2007cited by this paper
• Impact of Treatment of Gastroesophageal Reflux on Obstructive Sleep Apnea-Hypopnea Syndrome

  2007cited by this paper
• Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study.

  2006cited by this paper
• Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities

  2006cited by this paper
• Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.

  2006cited by this paper

• Breaking Ground: From CPAP Treatment to the First Medicine for OSA Patients with Obesity

  2025cites this paper
• Reduction of carbonic anhydrase activity is associated with amelioration of obstructive sleep apnea

  2025cites this paper
• Editorial: Novel technologies in the diagnosis and management of sleep-disordered breathing

  2024cites this paper
• The effect of sulthiame on potential biomarkers in moderate to severe obstructive sleep apnoea

  2024cites this paper
• Treatable Traits-Based Pharmacologic Treatment of Sleep Apnea.

  2024cites this paper
• Pharmacologic Therapy for Obstructive Sleep Apnea: Are We Seeing Some Light at the End of the Tunnel?

  2023cites this paper
• Modification of endotypic traits in obstructive sleep apnea by the carbonic anhydrase inhibitor sulthiame.

  2023cites this paper
• Eating habit of adding salt to foods and incident sleep apnea: a prospective cohort study

  2023cites this paper
• The placebo effect in pharmacological treatment of obstructive sleep apnea, a systematic review and meta-analysis.

  2023cites this paper
• Sleep apnea endotypes: from the physiological laboratory to scalable polysomnographic measures

  2023cites this paper
• Longitudinal Management and a Decision-Aid Tool in Treatment-Resistant Sleep Apnea

  2023cites this paper
• New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?

  2022cites this paper
• Arterial bicarbonate is associated with hypoxic burden and uncontrolled hypertension in obstructive sleep apnea - The ESADA cohort.

  2022cites this paper